



Immune Responses to COVID-19 Vaccines

Guest Editor:

Dr. Federico De Marco

Department of RDAT, the Regina
Elena National Cancer Institute
IRCCS, Via Elio Chianesi 53, 00144
Rome, Italy

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editor

Dear Colleagues,

Special Issue includes but is not restricted to the following:

- Use, efficacy, and safety of COVID-19 vaccines in frail persons such as, but not limited to, patients with cardiopulmonary chronic diseases, COPD, Diabetes, chronic renal failure, renal transplant carriers, and oncological/onco-hematological patients; in extreme ages (elderly/newborn), in pregnancy, in patients with chronic viral infections (HIV, HBV, or HCV), primary or secondary immune depression, or suffering for immune, allergic, or autoimmune diseases, either in treatment with immune modifying drugs or not
- Impact of COVID-19 vaccines in hospitalized/institutionalized persons and personnel and in special communities
- Off label use of COVID-19 vaccines: heterologous or mixed primer-booster schedules, extended prime to boost interval
- Interaction between COVID-19 vaccines and other vaccinations in newborns, in frail newborns (to an HIV/HBV/HCV-positive mother), in elderly, in multiple exposed frail patients
- Use and development of COVID-19 vaccines in medium–low-income countries or communities
- Next generation, new formulation, and new conception of COVID-19 vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)